Libero Santarpia

Libero Santarpia

UNVERIFIED PROFILE

Are you Libero Santarpia?   Register this Author

Register author
Libero Santarpia

Libero Santarpia

Publications by authors named "Libero Santarpia"

Are you Libero Santarpia?   Register this Author

64Publications

1302Reads

42Profile Views

Progress in nonviral gene therapy for breast cancer and what comes next?

Expert Opin Biol Ther 2017 05 22;17(5):595-611. Epub 2017 Mar 22.

a Oncology Experimental Therapeutics , IRCCS Clinical and Research Institute Humanitas , Rozzano ( Milan ), Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2017.1305351DOI Listing
May 2017

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.

Breast Cancer Res Treat 2016 12 15;160(3):439-446. Epub 2016 Oct 15.

MTA TTK Lendület Cancer Biomarker Research Group, Magyar Tudósok körútja 2, Budapest, 1117, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4013-7DOI Listing
December 2016

Role of inflammation in obesity-related breast cancer.

Curr Opin Pharmacol 2016 12 24;31:114-122. Epub 2016 Nov 24.

Oncology Experimental Therapeutics, IRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2016.11.004DOI Listing
December 2016

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Oncologist 2016 09 6;21(9):1063-78. Epub 2016 Jul 6.

Yale Cancer Center, School of Medicine, Yale University, New Haven, Connecticut, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016060PMC
September 2016

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.

Curr Cancer Drug Targets 2015 ;15(8):665-83

MTA TTK Lendület Cancer Biomarker Research Group, Magyar Tudosok Korutja 2, H-1117 Budapest, Hungary.

View Article

Download full-text PDF

Source
July 2016

Targeting microRNAs as key modulators of tumor immune response.

J Exp Clin Cancer Res 2016 Jun 27;35:103. Epub 2016 Jun 27.

Oncology Experimental Therapeutics Unit, IRCCS Humanitas Clinical and Research Institute, Rozzano-Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-016-0375-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924278PMC
June 2016

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

Cancer Res 2016 Feb 16;76(4):927-39. Epub 2015 Dec 16.

Institute for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755913PMC
February 2016

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.

Int J Cancer 2016 Jan 30;138(1):87-97. Epub 2015 Jul 30.

Oncology Experimental Therapeutics Unit, IRCCS Clinical and Research Institute Humanitas, Rozzano - Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29684DOI Listing
January 2016

Notch is a direct negative regulator of the DNA-damage response.

Nat Struct Mol Biol 2015 May 20;22(5):417-24. Epub 2015 Apr 20.

1] Istituto Fondazione Italiana per la Ricerca sul Cancro di Oncologia Molecolare, Milan, Italy. [2] Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerche, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nsmb.3013DOI Listing
May 2015

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.

Clin Cancer Res 2015 Mar 29;21(5):1207-14. Epub 2014 Dec 29.

Oncology Experimental Therapeutics Unit, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2011DOI Listing
March 2015

Targeting the microRNA-regulating DNA damage/repair pathways in cancer.

Expert Opin Biol Ther 2014 Nov 5;14(11):1667-83. Epub 2014 Sep 5.

IRCCS Clinical and Research Institute Humanitas, Experimental Therapeutics Unit , Via Manzoni 113 - 20089 Rozzano, Milan , Italy +39 02 8224 5173 ; +39 02 8224 5191 ; ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2014.950650DOI Listing
November 2014

A miRNA signature associated with human metastatic medullary thyroid carcinoma.

Endocr Relat Cancer 2013 Dec 14;20(6):809-23. Epub 2013 Oct 14.

Departments of Endocrine Neoplasia and Hormonal Disorders Experimental Therapeutics Urology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Department of Oncology, The University of Naples, Naples, Italy Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, Florence, Italy Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Houston, Texas, USA Department of Oncology, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy Department of Gynecologic Oncology, Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, University of Messina, Messina, Italy Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Department of Internal Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-13-0357DOI Listing
December 2013

Targeting triple negative breast cancer: is p53 the answer?

Cancer Treat Rev 2013 Aug 12;39(5):541-50. Epub 2013 Jan 12.

Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.12.001DOI Listing
August 2013

Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.

Curr Pharm Des 2013 ;19(5):864-82

Department of Oncology, Translational Research Unit, and Istituto Toscano Tumori, Prato - Italy.

View Article

Download full-text PDF

Source
July 2013

Circulating tumour cells and cell-free DNA as tools for managing breast cancer.

Nat Rev Clin Oncol 2013 Jul 28;10(7):377-89. Epub 2013 May 28.

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.80DOI Listing
July 2013

Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Int J Endocrinol 2013 21;2013:803171. Epub 2013 Feb 21.

Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, 50019 Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/803171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594951PMC
March 2013

Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.

Cytokine 2012 Aug 25;59(2):218-22. Epub 2012 May 25.

Department of Internal Medicine, University of Pisa - School of Medicine, Via Roma 67, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2012.04.042DOI Listing
August 2012

RET TKI: potential role in thyroid cancers.

Curr Oncol Rep 2012 Apr;14(2):97-104

Department of Internal Medicine, University of Pisa, School of Medicine, Via Roma 67, 56100 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-012-0217-0DOI Listing
April 2012

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.

Expert Opin Ther Targets 2012 Jan 12;16(1):103-19. Epub 2012 Jan 12.

The University of Texas M.D. Anderson Cancer Center, Department of Pathology, Houston, TX,USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2011.645805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457779PMC
January 2012

Adjuvant systemic treatment for individual patients with triple negative breast cancer.

Breast 2011 Oct;20 Suppl 3:S135-41

Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0960-9776(11)70311-3DOI Listing
October 2011

Triple negative breast cancer: a heterogeneous subgroup defined by what it is not.

Eur J Cancer 2011 Sep;47 Suppl 3:S370-2

Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano, Tumori, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0959-8049(11)70207-6DOI Listing
September 2011

Uncovering the metabolomic fingerprint of breast cancer.

Int J Biochem Cell Biol 2011 Jul 10;43(7):1010-20. Epub 2010 May 10.

Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2010.05.001DOI Listing
July 2011

Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.

Future Oncol 2011 Feb;7(2):173-86

Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.10.179DOI Listing
February 2011

Breast cancer assessment tools and optimizing adjuvant therapy.

Nat Rev Clin Oncol 2010 Dec 26;7(12):725-32. Epub 2010 Oct 26.

Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.170DOI Listing
December 2010

The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

Endocr Rev 2010 Aug 6;31(4):578-99. Epub 2010 Jul 6.

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/er.2009-0031DOI Listing
August 2010

Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.

Cancer 2010 Jun;116(12):2974-83

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25061DOI Listing
June 2010

MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype.

Endocr Relat Cancer 2010 Mar 29;17(1):F51-75. Epub 2010 Jan 29.

Translational Research Unit, Department of Oncology, Hospital of Prato and Istituto Toscana Tumori, Piazza dell' Ospedale, 59100 Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-09-0222DOI Listing
March 2010

Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.

Endocr Pract 2009 Sep-Oct;15(6):597-604

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/EP09148.RARDOI Listing
January 2010

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Cancer Treat Rev 2009 Dec 15;35(8):662-7. Epub 2009 Sep 15.

Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2009.08.006DOI Listing
December 2009

Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.

Anticancer Res 2009 Nov;29(11):4665-71

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109502PMC
November 2009

Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.

Hum Pathol 2009 Jun 5;40(6):827-33. Epub 2009 Feb 5.

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2008.11.003DOI Listing
June 2009

Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer.

Head Neck 2009 Mar;31(3):419-23

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hed.20911
Publisher Site
http://dx.doi.org/10.1002/hed.20911DOI Listing
March 2009

High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

J Clin Endocrinol Metab 2008 Nov 2;93(11):4367-72. Epub 2008 Sep 2.

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 433, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.
Publisher Site
http://dx.doi.org/10.1210/jc.2008-0912DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729231PMC
November 2008

Four patients with cutaneous metastases from medullary thyroid cancer.

Thyroid 2008 Aug;18(8):901-5

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2007.0179DOI Listing
August 2008

A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma.

Cancer Invest 2008 Jul;26(6):642-6

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/0735790070180252
Publisher Site
http://dx.doi.org/10.1080/07357900701802527DOI Listing
July 2008

Mosaicism in von Hippel-Lindau disease: an event important to recognize.

J Cell Mol Med 2007 Nov-Dec;11(6):1408-15

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1582-4934.2007.00122.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401302PMC
June 2008

Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.

Hum Pathol 2008 Jan 18;39(1):15-20. Epub 2007 Oct 18.

Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2007.05.012DOI Listing
January 2008

Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.

J Clin Endocrinol Metab 2008 Jan 7;93(1):278-84. Epub 2007 Nov 7.

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.
Publisher Site
http://dx.doi.org/10.1210/jc.2007-1076DOI Listing
January 2008

Germline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome.

Ann N Y Acad Sci 2006 Aug;1073:198-202

Sezione di Endocrinologia del Dipartimento Clinico Sperimentale di Medicina e Farmacologia Policlinico Universitario, Messina, I-98125, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1353.021DOI Listing
August 2006

Human thyroid autoantigens and proteins of Yersinia and Borrelia share amino acid sequence homology that includes binding motifs to HLA-DR molecules and T-cell receptor.

Thyroid 2006 Mar;16(3):225-36

Sezione di Endocrinologia del Dipartimento Clinico Sperimentale di Medicina e Farmacologia, Università di Messina, Messina, Italy.

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/thy.2006.16.225
Publisher Site
http://dx.doi.org/10.1089/thy.2006.16.225DOI Listing
March 2006

Homologies between proteins of Borrelia burgdorferi and thyroid autoantigens.

Thyroid 2004 Nov;14(11):964-6

Sezione di Endocrinologia del Dipartimento Clinico Sperimentale di Medicina e Farmacologia, Università di Messina, Messina, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2004.14.964DOI Listing
November 2004